Treatment strategies in EGFR-mutated NSCLC
Our latest Featured Discussion focused on Treatment Strategies in EGFR-Mutated NSCLC. Members from Lung Cancer Connect participated in peer-to-peer discussion regarding their concerns and interests on the topic. Below is a summary of highlights from the conversation:
- Your peers indicate that osimertinib is their preferred first-line therapy for NSCLC patients with sensitizing EGFR mutations as osimertinib has been the first-line standard-of-care therapy since its approval in April 2018.
- Although fellow members mention that they would consider the combination of EGFR TKI and VEGF therapy as an option through clinical trials, awareness around the recent approval for the combination of first-generation EGFR TKI erlotinib and VEGFR2 inhibitor ramucirumab remains low.
- Comments from your peers:
- “Osimertinib is typically first line, unless there are hurdles (insurance, patient access) or toxicity concerns (diarrhea, cytopenias, etc)”
- “Other combination agents may have additional clinical benefits, such as TKI and VEGF, with or without chemotherapy.”
- “Investigational studies are looking at the addition of VEGF directed therapy to the TKI as well the addition of chemotherapy to the TKI”
- “Clinical trials with TKI in combination with IO or chemo should also be considered if available and patient is willing for a clinical trial.”